S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in
OTCMKTS:OXBDF

Oxford Biomedica Stock Forecast, Price & News

$12.67
+0.01 (+0.08 %)
(As of 01/15/2021 10:01 PM ET)
Add
Compare
Today's Range
$12.36
Now: $12.67
$12.67
50-Day Range
$11.12
MA: $12.62
$14.25
52-Week Range
$4.51
Now: $12.67
$14.60
Volume700 shs
Average Volume2,500 shs
Market Capitalization$974.20 million
P/E RatioN/A
Dividend YieldN/A
Beta0.92
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development stage include OXB-302 that targets haematological tumours with a CAR-T 5T4; OXB-203, which is in pre-clinical stage for the treatment of wet age-related macular degeneration; OXB-202 for the treatment of corneal graft rejection; OXB-204, a lentiviral-based therapy for the ocular disease Leber's congenital amaurosis variant 10; OXB-103 (ALS) for central nervous system; and OXB-401 for liver indication. Its partnered products in development stage comprise AXO-Lenti-PD that is in a Phase I/II trial preparation for the treatment of Parkinson's disease; SAR 422459, which is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869 that is in Phase I/II trial for the treatment of Usher syndrome 1B. Oxford Biomedica plc has partnerships with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, Santen Pharmaceutical Co Ltd, Microsoft Research, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Papyrus Therapeutics, Inc. to assess the impact and therapeutic benefit of PYTX-002, a gene replacement therapy to confer cellular pharmacy properties on a CAR-T cell therapy. It has a discovery collaboration with PhoreMost Limited to develop CAR-T cell therapies. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
Oxford Biomedica logo

MarketRank

Overall MarketRank

0.48 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Private households
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:OXBDF
Previous SymbolNASDAQ:OXBDF
CUSIPN/A
CIKN/A
Phone44-18-6578-3000
Employees584

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$89.14 million

Profitability

Miscellaneous

Market Cap$974.20 million
Next Earnings DateN/A
OptionableNot Optionable
$12.67
+0.01 (+0.08 %)
(As of 01/15/2021 10:01 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OXBDF News and Ratings via Email

Sign-up to receive the latest news and ratings for OXBDF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Oxford Biomedica (OTCMKTS:OXBDF) Frequently Asked Questions

How has Oxford Biomedica's stock price been impacted by Coronavirus (COVID-19)?

Oxford Biomedica's stock was trading at $7.7250 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OXBDF shares have increased by 64.0% and is now trading at $12.67.
View which stocks have been most impacted by COVID-19
.

Is Oxford Biomedica a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford Biomedica in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Oxford Biomedica stock.
View analyst ratings for Oxford Biomedica
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Oxford Biomedica?

Wall Street analysts have given Oxford Biomedica a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Oxford Biomedica wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Oxford Biomedica?

Oxford Biomedica saw a decline in short interest in the month of December. As of December 31st, there was short interest totaling 7,100 shares, a decline of 26.0% from the December 15th total of 9,600 shares. Based on an average daily trading volume, of 5,100 shares, the short-interest ratio is presently 1.4 days.
View Oxford Biomedica's Short Interest
.

Who are some of Oxford Biomedica's key competitors?

Who are Oxford Biomedica's key executives?

Oxford Biomedica's management team includes the following people:
  • Mr. John Dawson, CEO & Exec. Director (Age 60)
  • Mr. Stuart Paynter, CFO, Company Sec. & Director (Age 47)
  • Mr. Nick Page, Chief Operations Officer
  • Dr. James Miskin Ph.D., Chief Technical Officer
  • Dr. Kyriacos Mitrophanous Ph.D., Chief Scientific Officer
  • Ms. Catherine Isted, Head of Corp. Devel. & IR
  • Ms. Natalie Louise Walter, Gen. Counsel
  • Ms. Sarah Macleod, Head of Communications
  • Ms. Helen Stephenson-Ellis, Chief People Officer
  • Dr. Richard Harrop D.Phil. B.Sc., Head of Clinical Analysis

What is Oxford Biomedica's stock symbol?

Oxford Biomedica trades on the OTCMKTS under the ticker symbol "OXBDF."

How do I buy shares of Oxford Biomedica?

Shares of OXBDF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Oxford Biomedica's stock price today?

One share of OXBDF stock can currently be purchased for approximately $12.67.

How big of a company is Oxford Biomedica?

Oxford Biomedica has a market capitalization of $974.20 million and generates $89.14 million in revenue each year. Oxford Biomedica employs 584 workers across the globe.

What is Oxford Biomedica's official website?

The official website for Oxford Biomedica is www.oxfordbiomedica.co.uk.

How can I contact Oxford Biomedica?

Oxford Biomedica's mailing address is Windrush Court Transport Way, Oxford X0, OX4 6LT. The company can be reached via phone at 44-18-6578-3000.

This page was last updated on 1/18/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.